Find information on thousands of medical conditions and prescription drugs.

Eligard

Leuprolide is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it intially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). more...

 Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF.

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron.

Read more at Wikipedia.org
• [List your site here Free!]


Medigene Ag Submits Eligard Maa To German Regulatory Agency
Atrix Laboratories, Inc. (Nasdaq: ATRX), Fort Collins, Colo., has announced that the company's European marketing partner, MediGene AG, has submitted ...
From Worldwide Biotech, 6/1/02
QLT announces trial court decision in ongoing Eligard® patent litigation and its intention to appeal
VANCOUVER, Jan. 20 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ:QLTI; TSX:QLT) announced a ruling in the on-going litigation between plaintiff TAP Pharmaceutical ...
From PR Newswire, 1/21/06
Six-Month Eligard FDA-Approved
It's estimated that nearly a quarter million men will be diagnosed with prostate cancer this year. In fact, the chances of developing the disease increase ...
From Business Wire, 4/5/05
German Regulatory Authority Completes Inspection Of Atrix
Atrix Laboratories, Inc. (NASDAQ:ATRX), Fort Collins, Colo., has announced that the German regulatory authority, Bundesinstitut fur Arzneimittel und ...
From Worldwide Biotech, 7/1/03
2002 biotech drug launches
The FDA has approved 20 new biotechnology-based drugs and vaccines as well as 15 new indications for previously approved biotech products in 2002. According to the Biotechnology Industry Organiza
From Drug Cost Management Report, 2/1/03
Treatment for prostate cancer gets under the skin
ELIGARD Atrix Laboratories has received FDA approval for a 3-month sustained-release treatment for advanced prostate cancer. Indicated for palliative ...
From Nursing, 11/1/02
Europe: French drug firm lists in New York
French pharmaceutical company Sanofi-Synthelabo listed American depositary receipts on the NewYork Stock Exchange. Sanofi-Synthelabo is a marketing partner ...
From Global Finance, 9/1/02 by Platt, Gordon
Fda Approves Atrix's Prostate Cancer Product
Atrix Laboratories, Inc. (Nasdaq: ATRX), Fort Collins, Colo., has received approval from the FDA for Eligard(TM) 7.5 mg (formerly Leuprogel One-Month ...
From Worldwide Biotech, 3/1/02

Home Contact Resources Exchange Links ebay